Prazosin Potentiates Mast Cell-Stabilizing Property of Adrenaline.
Level 5 - mechanism / opinion, no new human data
In vitro bench research using isolated rat peritoneal mast cells (no human subjects).
PubMed 38852193 · doi:10.33594/000000703
What was done
Researchers used the whole-cell patch-clamp technique to measure membrane capacitance (Cm) changes during GTP-γ-S-induced exocytosis in isolated rat peritoneal mast cells. They evaluated the effects of adrenaline on mast cell degranulation and capacitance changes in the presence or absence of the β2-adrenergic receptor antagonist butoxamine, as well as various α-adrenergic receptor agonists and antagonists, including the selective α1-blocker prazosin.
What was found
The abstract reports qualitative directions without specific numerical values, concentrations, or sample sizes. Adrenaline dose-dependently suppressed the GTP-γ-S-induced increase in Cm and inhibited mast cell degranulation; this effect was almost completely reversed by butoxamine. High-dose prazosin independently and significantly reduced the proportion of degranulating mast cells and suppressed the rise in Cm. When combined, prazosin augmented the inhibitory effect of adrenaline on degranulation.
Why it matters
This provides direct electrophysiological evidence of adrenaline's mast cell-stabilizing action via β2-receptors and suggests that α1-adrenergic blockade might enhance adrenaline's capacity to suppress mast cell activation.
Limits
The findings are derived entirely from in vitro rat peritoneal mast cells, which may differ physiologically from human tissue mast cells. The abstract does not provide exact cell counts, drug concentrations, or quantitative effect sizes. In vivo efficacy, pharmacokinetics, and clinical relevance for allergic conditions or anaphylaxis remain unstudied here.
Cited by
- contradicts Stress and adrenaline trigger the release of histamine.